Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People diagnosed with early-stage breast cancer (classified as cT1-2N1M0, meaning the tumour is a certain size, cancer has spread to nearby lymph nodes, but not to distant parts of the body)
- People who have had cancer confirmed in the armpit lymph nodes through a needle biopsy or tissue sample
- People who had 2 or fewer abnormal lymph nodes identified on imaging scans
- People who undergo a specific type of lymph node removal procedure called a Targeted Sentinel Node Biopsy (TSNB), where both a dye/tracer method and removal of a specially marked node are used
- People in whom 1 or 2 larger areas of cancer spread (called macrometastases) are found in the removed nodes, with at least 3 nodes removed in total
- People whose sentinel node could not be located during surgery may still be considered eligible if at least 3 nodes were removed and 1 or 2 macrometastases were found (confirm with trial site)
- People whose marked node was not successfully removed during surgery may still be considered eligible if at least 3 nodes were removed and 1 or 2 macrometastases were found (confirm with trial site)
- People whose tumour turns out to be slightly larger than expected when examined after surgery (T3 on post-operative pathology) may still remain eligible
Who may not be able to join:
- People who have received chemotherapy before surgery (neoadjuvant chemotherapy)
- People who have previously had lymph nodes removed from the same armpit side in an earlier procedure
- People with a larger tumour size at diagnosis (classified as cT3-4)
- People who had 3 or more abnormal lymph nodes identified on imaging scans
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Amit Goyal, University Hospitals of Derby and Burton NHS Foundation Trust
Phone: 01332 786958
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Patients with ≤2 nodal macrometastases identified on histology.; Patients with ≤2 nodal macrometastases identified on histology.; Patients with ≤2 nodal macrometastases identified on histology.; Patients with ≤2 nodal macrometastases identified on histology.; Patients with ≤2 nodal macrometastases identified on histology.; Identification rate of marked node; Identification rate of marked node; Identification rate of marked node; Identification rate of marked node; Identification rate of marked node; False negative rate of targeted sentinel node biopsy; False negative rate of targeted sentinel...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.